Quick Answer
Lineage Cell Therapeutics, Inc. reported Net Income Loss of -$63.53 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -241.4% in Net Income Loss from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: -$10.57 million | Q1 2015: -$10.17 million | Q2 2015: -$9.69 million | Q3 2015: -$13.63 million | Q4 2015: -$13.51 million | Q1 2016: -$17.11 million | Q2 2016: $24.55 million | Q3 2016: $31.20 million | Q4 2016: -$4.95 million | Q1 2017: $49.29 million | Q2 2017: -$11.65 million | Q3 2017: $14.32 million | Q4 2017: -$71.93 million | Q1 2018: -$63.55 million | Q2 2018: -$4.22 million | Q3 2018: $66.73 million | Q4 2018: -$44.95 million | Q1 2019: $39.31 million | Q2 2019: -$30.03 million | Q3 2019: -$16.51 million | Q4 2019: -$4.48 million | Q1 2020: -$8.40 million | Q2 2020: -$6.52 million | Q3 2020: -$7.76 million | Q4 2020: $2.03 million | Q1 2021: -$1.42 million | Q2 2021: -$4.79 million | Q3 2021: -$7.82 million | Q4 2021: -$28.99 million | Q1 2022: -$7.09 million | Q2 2022: -$6.76 million | Q3 2022: -$6.07 million | Q4 2022: -$6.35 million | Q1 2023: -$4.37 million | Q2 2023: -$5.23 million | Q3 2023: -$7.11 million | Q4 2023: -$4.78 million | Q1 2024: -$6.54 million | Q2 2024: -$5.76 million | Q3 2024: -$3.03 million | Q1 2025: -$4.14 million | Q2 2025: -$30.46 million | Q3 2025: -$29.78 million.
- Over the full 17 years of available data (2009 to 2025), Lineage Cell Therapeutics, Inc.'s Net Income Loss has declined by 1,135.0%.
- Historical annual values: Fiscal year 2025: -$63.53 million | Fiscal year 2024: -$18.61 million | Fiscal year 2023: -$21.49 million | Fiscal year 2022: -$26.27 million | Fiscal year 2021: -$43.02 million | Fiscal year 2020: -$20.65 million | Fiscal year 2019: -$11.71 million | Fiscal year 2018: -$45.99 million | Fiscal year 2017: -$19.98 million | Fiscal year 2016: $33.57 million | Fiscal year 2015: -$46.99 million | Fiscal year 2014: -$36.41 million | Fiscal year 2013: -$43.88 million | Fiscal year 2012: -$21.43 million | Fiscal year 2011: -$16.52 million | Fiscal year 2010: -$11.18 million | Fiscal year 2009: -$5.14 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: